

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number  
**WO 02/18000 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 15/00**

[SE/SE]; Hågavägen 3, S-647 32 Mariefred (SE). NILSSON, Lars-Gunnar [SE/SE]; Esplanaden 15E, S-731 30 Köping (SE).

(21) International Application Number: PCT/SE01/01683

(22) International Filing Date: 27 July 2001 (27.07.2001)

(74) Agents: HEDBERG, Åke et al.; Aros Patent AB, P.O. Box 1544, S-751 45 Uppsala (SE).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0003082-5 31 August 2000 (31.08.2000) SE

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): MICRO-DRUG AG [CH/CH]; Landweg 1, CH-6052 Hergiswil NW (CH).


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): NILSSON, Thomas

[Continued on next page]

(54) Title: METERED ELECTRO-DOSE



(57) Abstract: An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a metered medicament powder and is formed from an electro-powder constituting an active powder substance or a dry powder medicament formulation being transferred onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presents a fine particle fraction (FPF) having of the order 50 % or more of the content with a particle size between 0.5 to 5 µm. The electro-powder of such a metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 µC/g and presents a charge decay rate constant Q50 of more than 0.1 sec with a tap density of less than 0.8 g/ml. The electro-dose porosity is adjusted by means of mechanical and/or electrical vibration of the dose receiving device member during the electro-dose built-up operation to obtain an optimized porosity value of 75 to 99.9 % calculated as  $100 - 100 \cdot (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-dose}})$ . The method and the processing of electro-dose is partly illustrated by a flow-chart in which steps 220 to 270 present parameters necessary to be kept under strict control.



WO 02/18000 A1



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Declaration under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**Metered electro-dose****TECHNICAL FIELD**

The present invention relates to electrostatic dosing and more particularly to an electro-dose using electro-powder as well as a process and a method for preparation of a metered electro-dose for inhalation into the deep or upper lungs by means of an inhaler device.

**BACKGROUND**

The dosing of drugs is carried out in a number of different ways in the medicament service today. Within health care more and more is focused on the possibility of dosing medicament drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and patient-friendly administration of such substances.

A dry powder inhaler, DPI, represents a device intended for administration of powder into the deep or upper lung airways by oral inhalation. With deep lung should be understood the peripheral lung and alveoli, where direct transport of active substance to the blood can take place. Particle sizes, to reach into the deep lung, should be in a range 0.5 - 3  $\mu\text{m}$  and for a local lung delivery in the range 3 - 5  $\mu\text{m}$ . A larger grain size will easily stick in the mouth and throat, and a smaller grain size may accompany the expiration air out again.

To succeed with systemic delivery of medicament powders to the deep lung by inhalation there are some criteria, which have to be fulfilled. The most important is a very high degree of de-agglomeration of the medicament powder but also an exact dose is of great importance. This is not possible with dry powder inhalers of today without special arrangements as for example a so called spacer.

By means of a spacer the small grains are evenly distributed in a container from which the inhalation can take place. Upon inhalation from the spacer the fine powder floating free in the air will effectively reach the alveoli of the

lung. This method in principle has two drawbacks, firstly difficulties to control the amount of medicine emitted to the lung as an uncontrolled amount of powder sticks to the walls of the spacer and secondly difficulties in handling the relatively space demanding apparatus.

Powders for inhalers have a tendency of agglomerating, in other word to clod or to form small or larger lumps, which then have to be de-agglomerated. De-agglomeration is defined as breaking up agglomerated powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is performed as a stage one during dosing and as a final stage two during the patient's inspiration through the DPI.

Inhaler devices normally use the force exerted by the patient's more or less normal inspiration effort for de-agglomerating the medicament substance administered when inhaling in an effort to bring as much as possible of the active substance into the lungs. This often leads to inhaler designs using high pressure drops, which will put the patient's lungpower to the test.

One major problem with some of the techniques described above is to also obtain a low relative standard deviation (RSD) between doses with this type of technique due to lack of in line control possibilities in production making it hard to be in compliance with regulatory demands.

As already noted for an optimum amount of substance to reach the alveoli, an administered powder dose should preferably have a grain size between 0.5 and 3  $\mu\text{m}$ . Besides, the inspiration must take place in a calm way to decrease air speed and thereby reduce deposition in the upper respiratory tracts.

Technologies to de-agglomerate today include advanced mechanical and aerodynamic systems and combinations between electrical and mechanical filling systems that can be seen in for instance in U.S. Patent No. 5,826,633. Further there are systems disclosed for dispersing aerosolized doses of

medicaments, e.g. U.S. Patent No. 5,775,320, U.S. Patent No. 5,785,049, and U.S. Patent No. 5,740,794. Furthermore, in our International Publications WO 00/06236 and WO 00/06235 principles for de-agglomeration and classification are disclosed.

5

The term electro-powder refers to a micronized medicament powder presenting controlled electrostatic properties to be suitable for electrostatic administration in an inhaler device. Such an electro-powder provides possibilities for a better dosing from electrostatically operating equipment  
10 such as disclosed in our U.S. Patent No. 6,089,227 as well as our Swedish Patents No. 9802648-7 and 9802649-5, which present excellent inhalation dosing performance.

The state of the art also discloses a number of solutions for depositing  
15 powder for dosing. U.S. Patent No. 6,063,194 discloses a powder deposition apparatus for depositing grains on a substrate using an electrostatic chuck having one or more collection zones and using an optical detection for quantifying the amount of grains deposited. U.S. Patent No. 5,714,007 and U.S. patent No. 6,007,630 disclose an apparatuses for electrostatically  
20 depositing a medicament powder upon predefined regions of a substrate, the substrates being used to fabricate suppositories, inhalants, tablet capsules and the like. In U.S. Patent No. 5,699,649 and U.S. Patent No. 5,960,609 are presented metering and packaging methods and devices for pharmaceuticals and drugs, the methods using electrostatic phototechnology to package  
25 microgram quantities of fine powders in discrete capsule and tablet form.

Often, devices of prior art technology do not reach a sufficiently high degree of de-agglomeration and an exact dose is not well developed and leaves much to be desired when it comes to dosage conformity and lung deposition  
30 effectiveness of the medicament substance. Therefore, there is still a demand of pre-fabricated high accuracy pre-metered doses to be loaded into an inhaler device, which then will ensure repeated exact doses to be given. The active dry powder then must possess a fine particle fraction, which

guarantees its administration to a position within the lung of a patient where it will exert its expected effect.

## SUMMARY

5 An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a pre-metered medicament powder intended for use in a dry powder inhaler and is formed from an electro-powder constituting an active powder substance or a dry powder medicament formulation with or without one or more excipients, the electro-  
10 dose being loaded onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presenting a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5 and 5  $\mu\text{m}$ . The electro-powder of such a pre-metered electro-dose further provides electrostatic properties regarding absolute specific  
15 charge per mass after charging of the order 0.1 to 25  $\mu\text{C/g}$  and presents a charge decay rate constant  $Q_{50}$  of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity  $a_w$  of less than 0.5.

The electro-dose porosity is adjusted by means of a mechanical and/or  
20 electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value of 75 to 99.9% calculated as  $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$ . A number of parameters must be kept under strict control during the processing in order to obtain the desired electro-dose for utilization in a dry powder inhaler.

25 An electro-dose according to the present invention is set forth by the independent claim 1 and the dependent claims 2 to 6. Furthermore a method for obtaining an electro-dose is set forth by the independent claim 7 and further embodiments of the method are set forth by the dependent  
30 claims 8 to 23. Also a process for the manufacturing of an electro-dose is set forth by the independent claim 24 and the dependent claims 25 to 33.

## SHORT DESCRIPTION OF THE DRAWINGS

The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken together with the accompanying drawings, in which:

5

FIG. 1 is a simplified flow chart for creating an electro-dose from an electro-powder;

10

FIG. 2 is a flow chart illustrating the powder dose analysis when preparing the electro-dose;

FIG. 3 is a summary flow chart illustrating preparation of the electro-dose;

15

FIG. 4 illustrates a cross section of a dose carrier provided with a conducting or dissipative sheet for the preparation of an electro-dose by electric field technique methods;

20

FIG. 5 illustrates a cross section of a dose carrier made from a conductive or dissipative material for the preparation of an electro-dose by electric field technique methods;

25

FIG. 6 illustrates a cross section of a dose carrier containing a buried conductive material sheet inside an isolative material for the preparation of an electro-dose by means of electric field technique methods;

30

FIG. 7 illustrates a cross section of a dose carrier containing several separate buried conductive material sheets for the preparation of an electro-dose by electric field technique methods;

FIG. 8 illustrates transfer of electro-powder to a carrier by means of electric field techniques;

FIG. 9 illustrates transfer of electro-powder to the carrier by means of an electric field and a focusing means;

5 FIG. 10 illustrates a control circuitry utilized in the transfer of powder according to FIG. 9;

FIG. 11 illustrates an applied alternating electric field as function of time in transferring powder particles to the carrier;

10

FIG. 12 illustrates displacement of carrier surface in micrometers as a function of time;

15

FIG. 13 illustrates a "tree" structure in an enlarged view initial positioning of de-agglomerated particles at the carrier surface;

FIG. 14 illustrates a "sponge" structure in an enlarged view of particles positioned at the carrier surface after a compaction operation;

20 FIG. 15 illustrates in an enlarged view of a "velvet" structure of the particles at the carrier surface;

FIG. 16 is graph representing dose porosity and de-agglomeration for particles of sizes 3 and 5 micrometers;

25

FIG. 17 is a graph representing calculation of de-agglomeration for particles up to 3 micrometers from an initial electro-powder particle size;

30 FIG. 18 is a graph representing calculation of de-agglomeration for particles up to 5 micrometers from an initial electro-powder particle size; and



FIG. 19 shows a measurement set-up used for a measurement of size distribution and mass and further calculation of deagglomeration and flow rate.

## DESCRIPTION

In a starting step 100 of Figure 1 an electrostatically dosed electro-powder is brought into a powder dose analysis step 110. Dosing parameters are then determined in a step 120 to finally result in an electro-dose in a step 160. Electro-powder here is defined as a prepared active substance with or without one or more excipients meeting a set of electrical specifications for optimum electrostatic dosing properties. Specific charge is expressed in Coulomb per mass unit in this context as  $\mu\text{C/g}$  after charging. Such an electro-powder should present an absolute specific charge, after charging by induction, corona, or tribo-charging, of the order of 0.1 to 25  $\mu\text{C/g}$  ( $0.1 \times 10^{-6}$  –  $25 \times 10^{-6}$  Coulomb/gram of negative or positive charge) and a discharge rate constant  $Q_{50} > 0.1$  sec.  $Q_{50}$  is defined as the time until 50% of the electrostatic charge is discharged, (for instance after a corona charging in an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD). Furthermore the electro-powder should constitute a powder with more than 50 % of fine particle fraction with a particle size less than 5  $\mu\text{m}$  and have a water content of less than 4 % together with a water activity  $a_w < 0.5$ , preferably being between 0.2 and 0.3 and a tap density of less than 0.8 g/ml.

Water content is defined as the amount of weakly bound water. It's calculated as the difference between the total water content, determined e.g. by Karl-Fischer titration, and the amount of strongly bound water, e.g. crystal water, characteristic for the substance. Water activity  $a_w$  is a dimensionless quantity, which may, for instance, be measured with an AquaLab model series 3 TE. Tap density is, for instance, measured by using a Dual Autotap from Quantachrome® Corporation according to British Pharmacopoeia for Apparent Volume method. Both water activity and tap

density are quantities well known to a person skilled in the field of chemistry analysis.

All measurements are performed at room temperature defined as in a range of 18 - 25°C in air or nitrogen atmosphere with a relative humidity less than 5 %. The absolute specific charge is the charge the electro-powder presents after an electrostatic charging being performed and subsequently measured in  $\mu\text{C/g}$  with an electrometer, e.g. a Keithley Electrometer 6512 or an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD.

The electro-dose is then defined as an electrostatically dosed electro-powder possessing the following specification: Porosity defined as  $D_{p\text{electro-dose}} = 100 - 100(\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}}) > 75 \%$  and having a optimized de-agglomeration of  $> 25 \%$  and more preferable being more than 50 % and most preferable more than 75 % and meeting a dosage uniformity according to USP 24-NF 19 Supplement 601 Aerosols/Physical Tests pages 2674 - 2688, which will hereafter be referred to as USP, and also possessing a de-agglomeration difference measured according to USP compared with the de-agglomeration at a flow representing a pressure drop over the inhaler device reduced to 1 kPa  $(1 - (\text{de-agglomeration}(Q_{1\text{kPa}}) / \text{de-agglomeration}(Q)) \times 100) < 25 \%$  and more preferably less than 10 % and most preferably less than 5 %.

Particles intended for the deep lung, here defined as the peripheral lung and alveoli, where direct transport of an active substance to the blood can take place, should have a particle size in the range 0.5 - 3  $\mu\text{m}$ . For treatment in the local lung, defined as upper parts of the lung, where treatment normally takes place for instance in asthma treatment, the particle size should be in the range 3-5  $\mu\text{m}$ . All particle sizes are defined as the size of the particles measured with for instance a laser diffraction instrument e.g. a Malvern Mastersizer for physical size classification or an Andersen Impactor for an aerodynamic size classification and if not stated otherwise always referred to as aerodynamic particle size.

The active substance is a pharmacologically active chemical or biological substance, with or without one or more excipients intended for administration into the deep or upper lung airways by oral inhalation from a dry powder inhaler device (DPI), where inhaled macromolecules could be  
5 from the following therapeutic areas: Insulin rapid intermediate and slow acting and diabetes peptides, interferons, interleukins and antagonists, antibodies, peptides for immune suppression, nerve growth factors, vaccines, gene therapies, genetically modified virons and/or bacterias, parathyroid hormone, osteoporosis peptides, antiobesity peptides, luteinizing  
10 hormone releasing hormone (LHRH) and LHRH analogs, somatostatin analogs, human calcitonin, colony stimulating factor, erythropoietins, growth hormones, erectile dysfunction, anti-pregnancy hormones.

The active substance also could be selected from the pharmacologically  
15 active chemical and biological substances vasopressin, a vasopressin analogue, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, a somatostatin analogue, a gonadotropin agonist  
20 analogue, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, prolactin, an interleukin, a growth factor, a polypeptide vaccine, an enzyme, an endorphin, a glycoprotein, a lipoprotein kinas, intra-cellular receptors, transcription factors, gene transcription activators/repressors, neurotransmitters (natural or synthetic), proteo-  
25 glycans, a polypeptide involved in the blood coagulation cascade, that exerts its pharmacological effect systemically or any other polypeptide that has a molecular weight (Daltons) of up to 50 kDa or from the group consisting of proteins, polysaccharides, lipids, nucleic acids and combinations thereof or from the group consisting of leuprolide and albuterol or is among opiates or  
30 nicotine and nicotine derivates or scopolamin, morphine, apomorphine analoges or equivalent active substances or pharmacologically active chemicals for asthma treatment, e.g. budesonid, salbutamol, terbutalin-sulphate, salmeterol, flutikason, formoterol or salts thereof.

The first step **110** of the powder dose analysis includes a series of at least five powder doses to be analyzed in a step **210** illustrated in Figure 2. Standard settings of the input parameters are then used, which are well spread over an interval to have a possibility to in a sequence of steps **220** to **270** determine the most important specifications regarding height, area, mass, porosity and dose de-agglomeration at flow rate Q according to USP and Q<sub>1kPa</sub>. Very important is to determine if a porosity adjustment is necessary to be performed by active use of mechanical and/or electrical methods in the preparation of the electro-powder into an electro-dose by adjusting the dose porosity to an optimum giving an optimum inhalation performance regarding de-agglomeration. The porosity of the electro-dose is then defined as  $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$  producing a measure in percent.

Dose height is then measured in step **220** for the powder doses of step **210** using for instance a Laser displacement sensor from Keyence LK-031 with electronics LK-2001 and cables LK-C2 giving the height of the powder bed in  $\mu\text{m}$ .

The electro-powder doses tested in step **210** are then brought to step **230** for dose area investigation, wherein the projected size of the powder dose onto the device member is measured with, e.g., a stereo microscope from Olympus and noted down in millimeters with a resolution of 100  $\mu\text{m}$ .

A machine script is a program to control a sequence of operations inside a feeding device **45** in Figure 8, which is a device that in a controlled way is feeding electrostatically charged electro-powder into an electrical field allowing selected electro-powder particles with the right particle size to be transported to the device member and having a set of parameters added to the script to control the flexible settings of a powder dose. This electrostatic dosing device **45** is also performing a check of the absolute specific charge and all other essential parameters, e.g. feeding rate of de-agglomerated

electro-powder by the machine script. The dose de-agglomeration step **240** is defined as breaking up agglomerated electro-powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is performed as a stage one during dosing of the electro-powder and as a final stage two during the patient's inspiration of the electro-dose through the DPI. De-agglomeration is measured, e.g. using a Malvern Mastersizer as an example of a laser diffraction instrument used to measure particle size distribution both in aerosols and in liquids for physical size classification or an Andersen Impactor for an aerodynamic size classification as described in USP.

Table I

Dosing Time (s)	Vibration KHz; $\mu\text{m}$	Frequency $t_1; t_2; E_1; E_2$ s ; V	Electrical field E V/mm	Filter Potential $V_f$	Machine Script
8	0;0	0.5;0.01;250;-50	250	600	Test QC 1
8	0;0	0.5;0.01;250;-50	250	600	Test QC 1
8	0;0	0.5;0.01;250;-50	250	600	Test QC 1
8	0;0	0.5;0.01;250;-50	250	600	Test QC 1
8	0;0	0.5;0.01;250;-50	250	600	Test QC 1
8	0;0	0.5;0.01;300;-50	300	650	Test QC 1
8	0;0	0.5;0.01;350;-50	350	700	Test QC 1
8	0;0	0.5;0.01;400;-50	400	750	Test QC 1
8	0;0	0.5;0.01;500;-50	500	800	Test QC 1
8	0;0	0.5;0.01;1000;- 50	1000	1000	Test QC 1

The electro-powder de-agglomeration is performed in the electrostatic feeding device **45** where de-agglomeration and classifying of the electro-powder is performed then resulting in obtaining a majority of the powder particles being in the correct size range 0.5 - 5  $\mu\text{m}$  for being dosed onto the device member. This de-agglomeration operation is referred to as de-agglomeration #1 or electro-powder de-agglomeration.

The electro-dose de-agglomeration or de-agglomeration #2 takes place when sucking off the electro-dose from the device member accompanied with a de-agglomeration of the dose in the mouthpiece.

- 5 De-agglomeration #2 is measured as two different airflow values, whereby the first airflow  $Q$  is according to USP and the second airflow  $Q_{1kPa}$  is at a pressure drop over the inhaler device of 1 kPa. The two different airflow values are for determining if an increase in inhalation energy has a major effect on the de-agglomeration #2. It is important to minimize the effect of  
10 the inhalation energy by adjusting the de-agglomeration #2 and the dosing properties and de-agglomeration #1 to meet the electro-dose specification.

The electro-dose de-agglomeration is measured using a mouthpiece with a nozzle in the procedure which is identical to the construction and settings  
15 inside the DPI intended to be used and with a same device member as is to be used with the DPI. The portion at the end of the mouthpiece towards the device member has to be aerodynamically correctly constructed to minimize retention.

- 20 The de-agglomeration is then calculated using the electro-powder particle size specification as input material and the High Performance Liquid Chromatography HPLC analysis regarding particle size distribution after a standard sucking off from the device member as the output result. The de-agglomeration of the electro-dose is then calculated as percent of de-  
25 agglomerated electro-dose at  $3\text{ }\mu\text{m}$ ,  $DD_{3\mu\text{m}}$ , and  $5\text{ }\mu\text{m}$ ,  $DD_{5\mu\text{m}}$ , compared to the amount of powder less than  $3\text{ }\mu\text{m}$  and  $5\text{ }\mu\text{m}$  in the original electro-powder. The de-agglomeration must be more than 25 % to meet the electro-dose specification. Figure 17 and Figure 18 present calculations of de-agglomeration at  $3\text{ }\mu\text{m}$  and  $5\text{ }\mu\text{m}$ , respectively, in a graphical representation  
30 marking the areas under the particle size distribution curves for the initial and resulting distributions respectively. The curves plotted with dots representing initial electro-powder size distribution and the curves plotted with squares representing resulting electro-dose size distribution.

The dose mass in step **250** is possible to be measured in two different ways. First option is to use a Malvern Mastersizer, where the powder is collected on a filter after analysis through the instrument. The filter is then possible to analyze either using a balance, e.g. a Mettler Toledo UMT5 Ultra  
5 Microbalance or by chemical analyzes, e.g. a HPLC SpectraSYSTEM with a UV 6000 detector or any other suitable detector. A second option and also most preferable is to determine the powder mass using an Andersen Impactor and analyze both the aerodynamic particle size distribution and the total mass using for instance the HPLC SpectraSYSTEM with a UV 6000  
10 detector in accordance with USP.

To meet the electro-dose specification the mass must conform to the uniformity of dose stipulated in the USP and more preferably be between 95 % < label claim < 105 % when this will be possible by a proper control  
15 regarding the electro-powder and the electrostatic dosing device together with the machine script.

Results from the above analysis: dose height in step **220**, dose area in step **230**, dose de-agglomeration in step **240** and dose mass in step **250** is noted  
20 down for calculations.

Dose density is calculated from dose mass in micrograms from step **250** divided by dose height in millimeters from step **220** and divided by dose area in mm<sup>2</sup> from step **230** and noted down as dose density in µg/ mm<sup>3</sup> in step  
25 **260**. Dose porosity in step **265** is here defined in percent as  $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$  with the electro-powder density in this example being 1,4 kg/dm<sup>3</sup>. Dose mass per dose area is calculated in step **270** as dose mass in µg from step **250** divided by dose area from step **230** and noted as µg/mm<sup>2</sup>. The results are then combined with the settings  
30 presented in Table I and are presented with the results in Table II below.

Thus, all analytical results are noted down together with input data in an analytical report as step **280** forming a decision material for the step **120** of

Figure 1 determining dosing parameters. The result of this calculated example illustrates that, in order to obtain a high quality dose with respect to de-agglomeration in step **240**, the dose porosity obtained at step **265** should be to approximately 98 % .

5

Table II

Test	Dose height 220 $\mu\text{m}$	Dose area 230 $\text{mm}^2$	Dose de-aggl. 240		Dose mass 250 $\mu\text{g}$	Dose density 260 $\mu\text{g}/\text{mm}^3$	Dose Porosity 265 %	Dose mass/area 270 $\mu\text{g}/\text{mm}^2$
			3 $\mu\text{m}$ %	5 $\mu\text{m}$ %				
1	196	40	80	82	77	9	99.4	1.9
2	92	40	81	84	73	20	98.6	1.8
3	76	40	81	85	75	25	98.2	1.9
4	64	40	84	87	78	30	97.9	2.0
5	69	40	83	89	77	28	98.0	1.9
6	124	40	77	84	173	35	97.5	4.3
7	137	40	74	81	214	39	97.2	5.4
8	148	40	66	73	365	62	95.6	9.1
9	135	40	63	68	415	77	94.5	10.4
10	124	40	58	64	520	105	92.5	13.0

The decision in step **120** determining dosing parameters is then used to make several powder dosages in a step **130** for tests and to verify that the chosen settings are correct and verified in a step **140** according to a repeated step of powder dose analysis. If the result of this powder dose analysis proves to be according to set specification for an electro-dose the settings is noted down for the continued manufacturing process.

On the other hand, if powder dosing according to step **130** results are not within set specification for an electro-dose, the result is in a step **145** returned to the step **120** of determining dosing and parameters for a new optimized parameter settings. The determining preparation of electro-dose as a step **310** in Figure 3 is then taking into account the specification of the electro-powder in step **300** and dosing parameters in step **320** to have a new

20



set of tests for the preparation of the electro-dose. A very useful tool to optimize the electro-dose is to use a statistical planning method for the tests to reduce the total amount of tests needed and fast finding the optimum preparation scheme for a desired electro-dose.

5

Figure 4 shows an illustrative cross section a device member with a dissipative or conductive carrier area **14** as a dose receiver for the electro-dose and an isolative material **10**, e.g. plastic, having a surface resistance greater than  $10^{11} \Omega$ .

10

Figure 5 illustrates a cross section with another material as walls where the dissipative or conductive material **11** has a potential defined through an applied voltage **12** and where a conductive material is a material with a surface resistance  $< 10^6$  ohms or a dissipative material with a surface resistance between the conductive and the isolative material  $10^6 < \text{Dissipative material} < 10^{11}$  ohms.

15

Figure 6 shows in an illustrative cross section a device member with a dissipative or conductive material area **24** located under or behind a thin layer approximately 10-3000  $\mu\text{m}$  of isolative material **10** and where the dissipative or conductive material is having a set potential through an applied voltage **12**.

20

Figure 7 shows an illustrative cross section of a device member with two separate dissipative or conductive materials **22** and **24** and a isolative material **10**, where the dissipative or conductive material **24** forms the dose receiver of the electro-dose through an applied voltage **12** attracting the electrostatically charged electro-powder and the conductive material **22** is a conductive or dissipative material for applying a second electrical field to guide the powder to the correct position through a second applied voltage **18**.

25

30

In a further illustrative embodiment similar to Figure 5 the device member material forming the dose carrier may be chosen from an isolative plastic material, which is processed before dosing by ionized air to remove electrostatic charges from its surface. In another embodiment an isolative plastic material is processed before dosing by introducing the device member into humid air to remove electrostatic charge from its surface. In a third embodiment the device member isolative plastic material is processed before dosing by combination of ionized air and humid air to remove electrostatic charges from its surface.

In still a further embodiment the device member is temporarily given a dissipative surface by applying a thin solvent layer onto its surface, e.g. water, carbon dioxide or other non-toxic and FDA approved solvent. Such a solvent layer is then applied with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing removing the solvent from the device member.

Figure 8 shows in an illustrative example a dosing and metering set-up where a feeding device **45** for electrostatically charged electro-powder is subject to an electrical field **48** created by a separate applied potential **46** measured in V/mm and intended for transporting the electrostatically charged powder in a controlled way for dosing, metering or measuring purposes. A total field acts between the device member and the electro-powder feeder **45** through two different adjusted potentials **12** and **46**. Between the feeder **45** and the device member is situated a filter **44** to shield part of the device member not to be subject to dosing until the device member is in the correct position and then having a transportation of electrostatically charged electro-powder particles **49** metered onto the carrier portion of the device member.

Figure 9 shows an illustrative example of a dosing and metering set-up with a device member **11** made from a dissipative material at which powder is dosed by an applied electrical field between the feeder of electrostatically

charged electro-powder **45** and the device member utilizing an electrical filter **52** with a applied make-up potential to guide the powder to the correct position onto the carrier portion of the device member. The filter potential also serves as a possibility to control depositing on and off in a simple way  
5 by switching the applied voltage to the filter between normal potential and a much lower potential compared to the potential applied to the device member in this example. The guiding of electrostatically charged electro-powder particles **49** is then a function of applied voltage of the feeder of electrostatically charged electro-powder **49** and the voltage applied to the  
10 device member **12** and the potential of the filter **52**. The filter **52** is supported by an isolative filter holding material **44**.

Figure 10 shows in an illustrative example a dosing and metering set-up with a device member **11** in a dissipative material dosed onto by an applied  
15 electrical field between the feeder **45** of electrostatically charged electro-powder and the device member utilizing an electrical filter **52** with an applied make-up potential **59** to guide the powder to the correct position at the carrier portion of the device member **11**. The filter potential also serves as a possibility to control deposition on and off in a simple way by changing  
20 the potential of the filter **52**. The guiding of electrostatically charged electro-powder particles **49** is then a function of applied voltage to the feeder **45** of electrostatically charged electro-powder and the applied voltage to the device member **11** and the potential of the filter **52**. The filter **52** is supported by an isolative filter holding material **44**. The dose is possible to measure during  
25 the dosing and metering operation by using the electrometer **66** and switching the voltage **65** in front of a high voltage generator **67**. During the dosing and metering operation it is also possible to control the density of the electro-dose by utilizing a mechanical vibration **64** or an electrical frequency utilizing, e.g. the switching box **65** resulting in a possibility to control the  
30 electrical field and the mechanical movement according to Figures 11 and 12.

Figure 11 shows an example of electrical fields  $E_1$  and  $E_2$  applied as alternating fields at a pre-selected frequency to have the electro-powder to "dance" at the device member 11 to thereby achieve an optimum porosity for an optimum of de-agglomeration according to Figure 16. Figure 11 shows how the total dosing time period  $T$  is divided up in periods  $t_1$  when the electrical field is at a maximum value of  $E_1$  and other time periods  $t_2$  when the electrical field is at a minimum value of  $E_2$ , whereby the time periods  $t_1$  and  $t_2$  are in the range  $10^{-6} < t_1$ , and  $t_2 < 2$  seconds respectively.

Figure 12 illustrates an example of a set up with a mechanical vibration having a total dosing time period  $T$  and a maximum displacement of  $D_1$  during  $t_1$  and no displacement during the time period  $t_2$  to make the dosed electro-powder particles to "dance" at the device member 11 and thereby, by means of a control of the applied field, having a controlled adjustment of the porosity to an optimum situation for an optimized de-agglomeration according to Figure 16, whereby the time periods  $t_1$  and  $t_2$  are in the range  $10^{-6} < t_1$ , and  $t_2 < 2$  seconds, respectively.

Figure 13 shows a "tree" structure of powder particles at the device member 11 showing the ordering of particles of an electro-dose not being subject to adjustment of dose porosity disclosing chains of powder rising from the device member. The electro-powder particles 72 are forming "trees" of particles resulting in an extremely high porosity. The porosity of an electro-dose is calculated using the width and height of the "tree" structure together with the length to calculate the volume and then dividing the mass of the electro-dose with the volume to obtain the density of the electro-dose. The porosity is then calculated as  $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$  in percent, where the density of the electro-powder in this example is  $1.4 \text{ kg/dm}^3$ .

It should be noted that in the preferred process the carrier is turned with its receiving surface facing downwards as illustrated in Figures 13 to 15 when

picking up the charged particles **72**, **82** or **92**. However, the process may also be performed as indicated by Figures 6 to 10.

Figure 14 shows an electro-dose on the device member **11** with a "sponge" structure defined as an intermediate structure of the electro-dose, where some of the "tree" structures **82** have collapsed and are connected top to top forming a matrix with a medium to low density and less porosity through a adjusted density by electrical frequency or mechanical vibration during the dosing and metering operation thereby obtaining a lower porosity compared to the "tree" structure of Figure 13.

Figure 15 shows an electro-dose at a device member **11** presenting a velvet structure **92** after being porosity adjusted with the proper electrical frequency or mechanical vibration thereby obtaining a look like a smooth velvet cloth which shows much less porosity than the "sponge" structure.

Figure 16 illustrates the effect of a dose porosity adjustment in which the de-agglomeration of the electro-dose is measured at different porosities showing an optimum de-agglomeration both for particles less than 5  $\mu\text{m}$  and for particles less than 3  $\mu\text{m}$  having a porosity in the range marked as A also indicating that the electro-dose is independent of the flow at porosities inside the range A.

In the range marked B the de-agglomeration is in a transition area and showing medium flow dependence and a lower grade of de-agglomeration. In range C the porosity is lower and the powder much harder to de-agglomerate in dose de-agglomeration and also showing a strong dependence of the flow i.e. the energy level of the de-agglomeration #2 and are not suitable as an dose for inhalation and subject to optimization.  $DD_{5\mu\text{m}}$  is the dose de-agglomeration at 5  $\mu\text{m}$  and at a differential pressure according to USP and  $DD_{1\text{kPa}}$  is also according to USP but at a pressure drop over the inhaler of 1kPa.

Measurement of de-agglomeration is performed, e.g., according to Figure 19, using an Andersen Impactor together with a mouthpiece and a device member in a set-up identical with the intended DPI for the electro-dose or instead of the Andersen Impactor using a Malvern Master Sizer S to measure the physical particle size. When the particle distribution is measured the de-agglomeration can be calculated knowing the electro-powder particle size distribution.

The de-agglomeration is measured at two different rates of flow, flow-rate Q according to USP and at a flow-rate at 1 kPa pressure drop over the inhaler device according to USP. Measuring at two different flow-rates indicates if the electro-dose in the intended DPI is flow dependent or flow independent, as this may be an important aspect for the patient. If the difference in de-agglomeration is less than 25 %, when calculated as  $(100 - 100 \times (\text{de-agglomeration}(Q_{1\text{kPa}}) / \text{de-agglomeration}(Q)))$ , then the electro-dose meets the specifications, if the result is outside the electro-dose specifications further optimization of the electro-dose has to be performed by going back to step **310**.

Figure 17 describes how the de-agglomeration at 3  $\mu\text{m}$  is calculated using the initially input electro-powder under 3  $\mu\text{m}$  represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area with the calculated value of the surface of the first area and multiplying by a factor 100 the de-agglomerated amount below 3  $\mu\text{m}$  is obtained in percent.

Figure 18 describes how the de-agglomeration at 5  $\mu\text{m}$  is calculated using the initially input electro-powder under 5  $\mu\text{m}$  represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the

second area in Figure 18 with the calculated value of the surface of the first area in Figure 18 and multiplying by a factor 100 the de-agglomerated amount below 5  $\mu\text{m}$  is obtained in percent.

5 Figure 19 illustrates an example of a de-agglomeration and mass measurement set-up **71** identical to the inhaler to be used to determine the particle size distribution and mass from a pre-metered electro-dose sucked up from the device member **73** through a mouthpiece **78** using an Andersen Impactor **74** to determine the particle size distribution. The total pressure  
10 drop over the de-agglomeration set-up is measured with the pressure gauge **75** and the flow-rate of the air is measured with a flowmeter **76** in liters/minute. Suction may be achieved by means of a pumping device **77**.

All measurements of the particle size distribution are measured at two  
15 different pressure drops over the inhaler device. First all measurements are performed according to USP and then only the pressure is changed for the measurement at a lower pressure 1kPa over the inhaler device **71** in point **79**.

20 A complementary particle size distribution is also measured at 1kPa pressure drop over the de-agglomeration #2 set-up **71** indicated by the pressure gauge **79** as differential pressure to the atmosphere and then the obtained flow rate is noted down and named  $Q_{1\text{kPa}}$ . The particle size distribution obtained at the flow rate  $Q_{1\text{kPa}}$  is then compared with the  
25 particle size distribution obtained at the flow rate  $Q$ , using all other settings according to the USP. The results of the test of de-agglomeration #2 at two different pressures over the inhaler device are compared according to Figure 16 to determine if the result meets the specification for an electro-dose and also if the de-agglomeration for 3 and 5  $\mu\text{m}$ ,  $DD_{3\mu\text{m},1\text{kPa}}$  and  $DD_{5\mu\text{m},1\text{kPa}}$  are  
30 within the specifications of the medicament drug.

Thus the method and process according to the present disclosure will result in a very well defined electro-dose for utilization in a dry powder inhaler

resulting in a small standard deviation of the doses for repeated administrations.

5 It will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departure from the scope thereof, which is defined by the appended claims.



## CLAIMS

1. An electro-dose constituting a medicament powder for use in a dry powder inhaler, **characterized in** that the electro-dose is prepared from an electro-powder constituting an active powder substance or a dry powder medicament formulation, with or without one or more excipients, which is metered onto a device member forming a dose carrier, giving a fine particle fraction (FPF) presenting of the order 50 % or more of its content with a particle size between 0.5 and 5  $\mu\text{m}$ , the dose further presenting an optimized porosity of 75 to 99.9 %.

2. The electro-dose according to claim 1, **characterized in** that the metered electro-dose constitutes an electro-powder providing electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25  $\mu\text{C/g}$  and presents a charge decay rate constant  $Q_{50}$  of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity  $a_w$  of less than 0.5.

3. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, after analysis by a laser triangular method for a total volume calculation and a HPLC or weighing operation for determining the electro-dose mass, the porosity of the electro-dose, calculated in percent as  $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$ , presents a value between 75 and 99.9 %.

4. The electro-dose according to claim 1, **characterized in** that the metered electro-dose by using mechanical vibrations of the device member is adjusted to a porosity having a value between 75 and 99.9 %.

5. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, by using a frequency oscillation of an electrical field, is adjusted to a porosity having a value between 75 and 99.9 %.

6. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, onto a surface area of the device member forming a dose carrier, has a height less than 800  $\mu\text{m}$  perpendicular to the surface area of the device member onto which the electro-powder is deposited.

5

7. A method for preparing a metered electro-dose of electro-powder for administration into the deep or upper lung airways by oral inhalation using a dry powder inhaler device, **characterized by** the steps of:

charging by means of corona, induction or tribo-effect a medicament powder, being a preparation of chemical and biological substance, with or without one or more excipients, forming an electro-powder;

transporting charged particles towards a device member constituting a dose carrier using electric field techniques;

depositing the charged particles onto the dose carrier using electrical field techniques;

forming of a metered electro-dose bed onto the dose carrier using electrical field techniques.

8. The method according to claim 7, **characterized by** the further step of combining the electrical field techniques with a mechanical vibration and/or an applied electrical frequency to adjust the dose porosity.

9. The method according to claim 7, **characterized by** the further step of analyzing the metered electro-dose bed regarding one or more of at least following parameters: dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity.

10. The method according to claim 7, **characterized by** the further step of comparing the analysis result with predefined dosing parameters for deciding that the metered electro-dose at the dose carrier complies with the basic requirements for administration by the inhaler device.

11. The method according to claim 7, **characterized by** the further step of checking that the metered electro-dose has an optimized porosity of 75 to 99.9 %.

12. The method according to claim 7, **characterized by** the further step of utilizing mechanical vibration of the dose receiving device member during the dosing operation to adjust the metered electro-dose powder porosity to an optimized value between 75 and 99.9 %.

13. The method according to claim 7, **characterized by** the further step of analyzing the metered electro-dose by a laser triangular method and a HPLC or weighing operation for a total volume calculation to determine the electro-dose mass in order to calculate the electro-dose powder porosity in percent as  $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$  obtaining an optimized value between 75 and 99.9 %.

14. The method according to claim 7, **characterized by** the further step of preparing the metered electro-dose onto a surface area of the device member, to obtain an electro-dose height of less than 800  $\mu\text{m}$ .

15. The method according to claim 14, **characterized by** the further step of checking the metered electro-dose height by means of a triangular laser measuring instrument.

16. The method according to claim 7, **characterized by** the further step of additionally preparing the pre-metered electro-dose by using an oscillating electrical field to adjust the porosity of the electro-dose to an optimized value of 75 to 99.9 %.

17. The method according to claim 7, **characterized by** the further step of preparing the electro-dose using at least one active electrical filter with a control potential switched on and off within a voltage range  $V_{\text{low electrical field}} \leq V_{\text{filter}} \leq V_{\text{device member}}$  during the metering process and using an opening area

per controlled opening of the active electrical filter in a range of  $0.02 \leq \text{Filter opening} \leq 75 \text{ mm}^2$ .

18. The method according to claim 7, **characterized by** the further step  
5 of measuring metered electro-dose mass by draining the electrostatic charge  
into a electrometer determining the specific charge in  $\mu\text{C}/g_{\text{electro-powder}}$ .

19. The method according to claim 7, **characterized by** the further step  
10 of measuring metered electro-dose height using a contrast analyzing method  
and checking height of the electro-dose to be less than  $800 \mu\text{m}$ .

20. The method according to claim 7, **characterized by** the further step  
of measuring metered electro-dose height using a laser triangulation method  
and checking height of the electro-dose to be less than  $800 \mu\text{m}$ .

15 21. The method according to claim 7, **characterized by** the further step  
of measuring metered electro-dose height using an image analyzing method  
and checking height of the electro-dose to be less than  $800 \mu\text{m}$ .

20 22. The method according to claim 7, **characterized by** the further step  
of measuring metered electro-dose height using a combination of image  
analysis, laser triangulation, contrast methods to ensure a height of the  
electro-dose to be less than  $800 \mu\text{m}$ .

25 23. The method according to claim 7, **characterized by** the further step  
of measuring electro-dose deagglomeration using a Andersen Impactor for  
aerodynamic particle size distribution or a Malvern Mastersizer S to  
determine the physical particle size distribution for a calculation and  
optimization of the deagglomeration of the electro-dose by changing the  
30 porosity.

24. A process of preparing doses of powder to be used for administration  
by a dry powder inhaler, **characterized in** that

a medicament powder, being a preparation of a chemical and/or biological substance, with or without one or more excipients, forming an electro-powder, is metered onto a device member constituting a dose carrier thereby forming a metered electro-dose;

5 a metered electro-dose bed is formed on the dose carrier material using electrical field techniques;

the obtained metered electro-dose bed is analyzed regarding one or more of at least following parameters: dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity; and

10 a result of the analysis is compared with predefined dosing parameters for deciding that the prepared metered electro-dose of powder on the dose carrier complies with the basic requirements for administration by the inhaler.

15 25. The process according to claim 24, **characterized in** that electrical field technology is combined with a mechanical vibration and/or an applied electrical frequency.

20 26. The process according to claim 24, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by ionized air to remove electrostatic charges from its surface.

25 27. The process according to claim 24, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by introducing the device member into humid air to remove electrostatic charge from its surface.

30 28. The process according to claim 24, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by combination of ionized air and humid air to remove electrostatic charges from its surface.

29. The process according to claim 24, **characterized in** that electro-conductive material is mixed into a plastic material constituting the device member.

5 30. The process according to claim 24, **characterized in** that electro-conductive material is coated onto a plastic material constituting the device member.

31. The process according to claim 29 or 30, **characterized in** that the  
10 conductive material and the plastic material combination of the device member has a specification presenting a surface resistance of  $10^3 - 10^{12} \Omega$ , and a volume resistivity of  $10^3 - 10^{12} \text{ ohm}\cdot\text{m}$ .

32. The process according to claim 24, **characterized in** that electro-  
15 conductive material used for the device member is obtained from any of materials such as silver powder, platinum powder, gold powder, stainless steel powder, antimony-doped tin oxide, antimony-doped silica oxide, or is a X-doped silica where X is an adamantine semiconductor, e.g., Ge, ZnO, GaSb or an octahedral semiconductor, e.g. SnSe, AgSbSe<sub>2</sub>, InSb or carbon or  
20 any other electro-conductive material approved by FDA and possible to incorporate into plastics.

33. The process according to claim 24, **characterized in** that the device member is temporarily given a dissipative surface by applying a thin solvent  
25 layer onto the surface e.g. water, carbon dioxide or other non-toxic and FDA approved solvent with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing and metering removing the solvent from the device member.




Fig. 1

2/13




Fig. 2






Fig. 3

4/13




Fig. 4




Fig. 5

5/13




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig.10

9/13




Fig. 11




Fig. 12

10/13




Fig. 13




Fig. 14



11/13




Fig. 15




Fig. 16

12/13




Fig. 17




Fig. 18




Fig. 19

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01683

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61M 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9700704 A1 (NILSSON, LARS, GUNNAR), 9 January 1997 (09.01.97) --	1-33
A	WO 9832479 A1 (ABRAMS, ANDREW, L. ET AL), 30 July 1998 (30.07.98) --	1-33
A	WO 0006235 A1 (MICRODRUG AG), 10 February 2000 (10.02.00) --	1-33
A	WO 0006236 A1 (MICRODRUG AG), 10 February 2000 (10.02.00) -- -----	1-33

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

29 October 2001

Date of mailing of the international search report

30 -10- 2001

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Jack Hedlund/Els  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01683

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9700704	A1	09/01/97	AU	697654 B	15/10/98
				AU	6247496 A	22/01/97
				CA	2224929 A	09/01/97
				CN	1192703 A	09/09/98
				EP	0836496 A	22/04/98
				JP	11508161 T	21/07/99
				SE	504458 C	17/02/97
				SE	9502262 A	22/12/96
				US	6089227 A	18/07/00
WO	9832479	A1	30/07/98	AU	3214097 A	18/08/98
				US	5694920 A	09/12/97
WO	0006235	A1	10/02/00	AU	5076899 A	21/02/00
				BR	9912593 A	02/05/01
				CN	1311702 T	05/09/01
				EP	1100571 A	23/05/01
				SE	512386 C	06/03/00
				SE	9802649 A	31/01/00
WO	0006236	A1	10/02/00	AU	5076999 A	21/02/00
				BR	9912592 A	02/05/01
				CN	1311701 T	05/09/01
				EP	1100572 A	23/05/01
				SE	512433 C	13/03/00
				SE	9802648 A	31/01/00